Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Camm, A. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Camm, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

How does pure heart rate lowering impact on cardiac tolerability?

A. John Camm{dagger}

Division of Cardiac and Vascular Sciences, St George's University of London, Cranmer Terrace, London SW17 0RE, UK

Corresponding author. Tel: +44 20 8725 3554; fax: +44 20 8767 7141. E-mail address: jcamm{at}sgul.ac.uk

By selectively and specifically inhibiting the cardiac pacemaker If current, the If inhibitors lower heart rate without compromising myocardial contractility, haemodynamic status, or the electrophysiological properties of the heart. The first agent in this class, ivabradine, has completed its large clinical development programme, for which the cardiac tolerability data cover nearly 5000 patients, about 3500 of whom received the agent. Examination of the data shows that If inhibition with ivabradine constitutes an effective anti-anginal and anti-ischaemic therapy; cardiac adverse events were reported at a rate that is acceptable for a population with stable angina. Among the other adverse events, the most frequently reported were visual symptoms, which are related to retinal Ih inhibition and often resolve during treatment. Ivabradine is associated with significant increases in sinus node recovery time and uncorrected QT interval, which are related to heart rate, but had no significant effect on any other electrophysiological parameter. Correction of the QT interval using a population correction formula confirmed that ivabradine has no significant effect on the duration of ventricular repolarization, i.e. no proarrhythmic effect. Ivabradine produced no negative inotropic effect even in the presence of left ventricular (LV) systolic dysfunction. Preliminary clinical data suggest that ivabradine has a beneficial effect on cardiac performance and LV geometry. These results are currently being tested in the ongoing morBidity–mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.

Key Words: Heart rate • If inhibition • Ivabradine • Cardiac tolerability • Sinus bradycardia • Cardiac electrophysiology • QT interval • Myocardial contractility


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.